Endoxifen: A new, protein kinase C inhibitor to treat acute and mixed mania associated with bipolar I disorder

Endoxifen is a protein kinase C inhibitor. The objective of the present phase III study was to demonstrate the safety and efficacy of endoxifen in treating bipolar I disorder (BPD I) patients.

• Publication year

  2020

• Venue

  Bipolar Disorders

• Publication date

  2020-12-25

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/bdi.13041PMID 33368969
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Valproate for acute mania.

  2019cited by this paper
• Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder

  2018cited by this paper
• Clinically relevant response and remission outcomes in cariprazine-treated patients with bipolar I disorder.

  2018cited by this paper
• Assessment of atherosclerotic risk among patients with epilepsy on valproic acid, lamotrigine, and carbamazepine treatment

  2017cited by this paper
• The Risk of Thrombocytopenia During Valproic Acid Therapy: A Critical Summary of Available Clinical Data

  2017cited by this paper
• Clinical Practice Guidelines for Management of Bipolar Disorder

  2017cited by this paper
• Role of Protein Kinase C in Bipolar Disorder: A Review of the Current Literature

  2017cited by this paper
• Treatment-adherence in bipolar disorder: A patient-centred approach

  2016cited by this paper
• Effects of antiepileptic drug on thyroid hormones in patients with epilepsy: A meta-analysis.

  2016cited by this paper
• Endoxifen, a New Treatment Option for Mania: A Double‐Blind, Active‐Controlled Trial Demonstrates the Antimanic Efficacy of Endoxifen

  2016cited by this paper
• Tamoxifen: A Protein Kinase C Inhibitor to Treat Mania A Systematic Review and Meta-Analysis of Randomized, Placebo-Controlled Trials

  2016cited by this paper
• Protein Kinase C Inhibition Rescues Manic-Like Behaviors and Hippocampal Cell Proliferation Deficits in the Sleep Deprivation Model of Mania

  2015cited by this paper
• Cariprazine in the treatment of acute mania in bipolar I disorder: a double-blind, placebo-controlled, phase III trial.

  2015cited by this paper
• Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial

  2015cited by this paper
• Novel CNS‐Permeant PKC Inhibitor And Tamoxifen Analog Reduces Amphetamine Neurochemical And Behavioral Effects

  2015cited by this paper
• Tamoxifen metabolism predicts drug concentrations and outcome in premenopausal patients with early breast cancer

  2014cited by this paper
• A network meta-analysis on comparative efficacy and all-cause discontinuation of antimanic treatments in acute bipolar mania

  2014cited by this paper
• Towards the clinical implementation of pharmacogenetics in bipolar disorder

  2014cited by this paper
• A four week randomised control trial of adjunctive medroxyprogesterone and tamoxifen in women with mania.

  2014cited by this paper
• Clinical Significance of Treatment Effects with Aripiprazole versus Placebo in a Study of Manic or Mixed Episodes Associated with Pediatric Bipolar I Disorder

  2013cited by this paper
• Paliperidone extended-release as adjunctive therapy to lithium or valproate in the treatment of acute mania: a randomized, placebo-controlled study.

  2011cited by this paper
• Efficacy of Antimanic Treatments: Meta-analysis of Randomized, Controlled Trials

  2011cited by this paper
• Columbia-Suicide Severity Rating Scale (C-SSRS)

  2011cited by this paper
• Double-blind, randomized, placebo-controlled 6-week study on the efficacy and safety of the tamoxifen adjunctive to lithium in acute bipolar mania.

  2011cited by this paper
• Efficacy of Sodium Valproate and Haloperidol in the Management of Acute Mania: A Randomized Open‐Label Comparative Study

  2010cited by this paper
• Endoxifen, a New Cornerstone of Breast Cancer Therapy: Demonstration of Safety, Tolerability, and Systemic Bioavailability in Healthy Human Subjects

  2010cited by this paper
• Endoxifen is a new potent inhibitor of PKC: a potential therapeutic agent for bipolar disorder.

  2010cited by this paper
• Protein Kinase C Inhibitors

  2009cited by this paper
• Protein kinase C inhibition in the treatment of mania: a double-blind, placebo-controlled trial of tamoxifen.

  2008cited by this paper
• Weight gain and metabolic issues of medicines used for bipolar disorder

  2007cited by this paper
• Weight gain and recovery of pre-cancer weight after breast cancer treatments: evidence from the women’s healthy eating and living (WHEL) study

  2007cited by this paper
• Efficacy of a protein kinase C inhibitor (tamoxifen) in the treatment of acute mania: a pilot study.

  2007cited by this paper
• Rates of remission/euthymia with quetiapine monotherapy compared with placebo in patients with acute mania.

  2007cited by this paper
• The armamentarium of treatments for bipolar disorder: a review of the literature.

  2007cited by this paper
• A pilot study of hormone modulation as a new treatment for mania in women with bipolar affective disorder.

  2006cited by this paper
• Acute and continuation risperidone monotherapy in bipolar mania: a 3-week placebo-controlled trial followed by a 9-week double-blind trial of risperidone and haloperidol.

  2005cited by this paper
• Quetiapine with lithium or divalproex for the treatment of bipolar mania: a randomized, double-blind, placebo-controlled study.

  2004cited by this paper
• Mood stabilisers plus risperidone or placebo in the treatment of acute mania

  2003cited by this paper
• Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial.

  2003cited by this paper
• Practice guideline for the treatment of patients with bipolar disorder, second edition.

  2002cited by this paper
• Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy.

  2002cited by this paper
• Tamoxifen-induced thrombocytopenia.

  1999cited by this paper
• Modification of the Clinical Global Impressions (CGI) Scale for use in bipolar illness (BP): the CGI-BP.

  1997cited by this paper
• "It's the genes, stupid". Molecular bases and clinical consequences of genetic cytochrome P450 2D6 polymorphism.

  1995cited by this paper
• The effect of tamoxifen treatment on serum cholesterol fractions in breast cancer women.

  1994cited by this paper
• Long‐term action of lithium: A role for transcriptional and posttranscriptional factors regulated by protein kinase C

  1994cited by this paper
• Distribution of tamoxifen and metabolites into brain tissue and brain metastases in breast cancer patients.

  1991cited by this paper
• A New Depression Scale Designed to be Sensitive to Change

  1979cited by this paper
• A Rating Scale for Mania: Reliability, Validity and Sensitivity

  1978cited by this paper

• Clinical practice guidelines for the management of bipolar disorder: 2025 update

  2026cites this paper
• Medications for the Management of Suicidal Behavior: Precision Psychiatry in Evolution

  2025cites this paper
• Evaluation of (Z)-endoxifen as a potential therapy for glioblastoma multiforme through computational and experimental analyses

  2025cites this paper
• Adjunctive Use of Endoxifen in Trichotillomania: A Case Series from a Tertiary Psychiatry Setting in India.

  2025cites this paper
• Management of internet addiction in an 18-year-old female with endoxifen: a case report

  2025cites this paper
• Improvement of schizoaffective disorder with endoxifen treatment: a case report

  2025cites this paper
• Managing Impulsivity and Substance Abuse in an Adolescent with Attention-deficit Hyperactivity Disorder: Potential for Endoxifen Therapy.

  2025cites this paper
• Successful treatment of endoxifen overdose: A case report

  2025cites this paper
• Treatment resistance and treatment intolerance in Mania: Lesson learned and way ahead

  2025cites this paper
• Endoxifen in Bipolar Disorder With Hyperammonemia and Renal Impairment: A Case Report

  2025cites this paper
• Recent advances in PKC inhibitor development: Structural design strategies and therapeutic applications.

  2025cites this paper
• Endoxifen Usage in Bipolar Disorders Patients: My Experiential Journey

  2024cites this paper
• New Advances in the Pharmacology and Toxicology of Lithium: A Neurobiologically Oriented Overview

  2024cites this paper
• Efficacy and safety of endoxifen in bipolar disorder: A systematic review

  2024influential citation
• Research on clinical aspects of bipolar disorder: A review of Indian studies

  2024cites this paper
• Targeting Neurotransmitter Systems in Bipolar Disorder: A comprehensive Review of novel pharmacological approaches

  2024influential citation
• Endoxifen for the Management of Pathological Gambling in a Male Patient Who Overinvested in Cryptocurrency: A Case Report

  2024cites this paper
• The Antimanic Effect of Endoxifen in Patients with Bipolar Disorder with Renal Comorbidities: Case Series.

  2024cites this paper
• Characterizing the Most Vulnerable Prefrontal Cortical Neurons in Schizophrenia.

  2024cites this paper
• Endoxifen dual benefits, alleviating symptoms of bipolar disorder, and a potential novel anticraving agent for alcohol dependence: A case series

  2024cites this paper
• RNA Editing Signatures Powered by Artificial Intelligence: A New Frontier in Differentiating Schizophrenia, Bipolar, and Schizoaffective Disorders

  2024cites this paper
• Non-canonical pathways in the pathophysiology and therapeutics of bipolar disorder

  2023cites this paper
• Endoxifen in Treatment of Individuals with Borderline Personality Disorder with Predominant Impulsivity: A Case Series

  2023cites this paper
• Endoxifen Approval for Bipolar Disorder in India: A Premature or a Pragmatic Decision?

  2023cites this paper
• An Update on Protein Kinases as Therapeutic Targets—Part I: Protein Kinase C Activation and Its Role in Cancer and Cardiovascular Diseases

  2023cites this paper
• Endoxifen for the management of bipolar disorder with comorbid substance use disorder: A report of two cases

  2023cites this paper
• Real world experience of Endoxifen augmentation therapy in a case of resistant OCD

  2023cites this paper
• Existing and emerging pharmacological approaches to the treatment of mania: A critical overview

  2022cites this paper
• Long-term effectiveness and safety of endoxifen in the treatment of bipolar mania: a case report

  2022cites this paper
• Real-World Long-Term Experience on Endoxifen in Bipolar Disorder with Psychotic Symptoms

  2022cites this paper
• Effects of tamoxifen alone and in combination with risperidone on hyperlocomotion, hippocampal structure and bone in ketamine-induced model of psychosis in rats

  2022cites this paper
• Intracellular signaling cascades in bipolar disorder

  2022cites this paper
• Impact of organic anion transporting polypeptide, P-glycoprotein, and breast cancer resistance protein transporters on observed tamoxifen and endoxifen concentration and adverse effects

  2022cites this paper
• Endoxifen, an Estrogen Receptor Targeted Therapy: from Bench to Bedside.

  2021cites this paper
• Reply to Ghosh et al1. Comments on Endoxifen: A new, protein kinase C inhibitor to treat acute and mixed mania associated with bipolar I disorder

  2021cites this paper
• Efficacy of endoxifen, a protein kinase C inhibitor for acute and mixed mania: Some concerns worth considering

  2021cites this paper